FDG-PET has no definite role in preoperative imaging in gastric cancer

European Journal of Surgical Oncology

Volumn 35, Issue 5, 2009, Pages 449-455

  Dassen, A E ^a   Lips, D J ^a   Hoekstra, C J ^a   Pruijt, J F M ^a   Bosscha, K ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

FDG PET; Gastric cancer; Response monitoring; Review; Staging

Indexed keywords

3' FLUOROTHYMIDINE F 18; DEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; TRACER;

ADJUVANT CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; IMAGING; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METASTASIS; MONITORING; MORTALITY; PERITONEUM CANCER; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR RECURRENCE;

CHEMOTHERAPY, ADJUVANT; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 63049101642     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.11.010     Document Type: Review

References (44)

1. Bentrem D., Gerdes H., Tang L., Brennan M., and Coit D. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol 14 6 (2007) 1853-1859
2. Lowy A.M., Mansfield P.F., Leach S.D., and Ajani J. Laparoscopic staging for gastric cancer. Surgery 119 6 (1996) 611-614
3. Burke E.C., Karpeh M.S., Conlon K.C., and Brennan M.F. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 225 3 (1997) 262-267
4. Kim S.K., Kang K.W., Lee J.S., et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 33 2 (2006) 148-155
5. Yun M., Lim J.S., Noh S.H., et al. Lymph node staging of gastric cancer using (18) F-FDG PET: a comparison study with CT. J Nucl Med 46 10 (2005) 1582-1588
6. IKC. Available from: (2008). www.oncoline.nl Ref type: internet communication
7. Sarela A.I., Miner T.J., Karpeh M.S., Coit D.G., Jaques D.P., and Brennan M.F. Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg 243 2 (2006) 189-195
8. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8 9 (2007) 797-805
9. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343 4 (2000) 254-261
10. Mijnhout G.S., Hooft L., van Tulder M.W., Deville W.L., Teule G.J., and Hoekstra O.S. How to perform a comprehensive search for FDG-PET literature. Eur J Nucl Med 27 1 (2000) 91-97
11. Chen J., Cheong J.H., Yun M.J., et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 103 11 (2005) 2383-2390
12. Ott K., Fink U., Becker K., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21 24 (2003) 4604-4610
13. Shoda H., Kakugawa Y., Saito D., et al. Evaluation of 18F-2-Deoxy-2-Fluoro-Glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 97 11 (2007) 1493-1498
14. Di F.F., Pinto C., Rojas Llimpe F.L., et al. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 10 4 (2007) 221-227
15. Stahl A., Ott K., Weber W.A., et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30 2 (2003) 288-295
16. Mukai K., Ishida Y., Okajima K., Isozaki H., Morimoto T., and Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 9 3 (2006) 192-196
17. Mochiki E., Kuwano H., Katoh H., Asao T., Oriuchi N., and Endo K. Evaluation of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography for gastric cancer. World J Surg 28 3 (2004) 247-253
18. Yeung H.W., Macapinlac H., Karpeh M., Finn R.D., and Larson S.M. Accuracy of FDG-PET in gastric cancer. Preliminary experience. Clin Positron Imaging 1 4 (1998) 213-221
19. Yoshioka T., Yamaguchi K., Kubota K., et al. Evaluation of 18F-FDG PET in patients with a, metastatic, or recurrent gastric cancer. J Nucl Med 44 5 (2003) 690-699
20. Lim J.S., Kim M.J., Yun M.J., et al. Comparison of CT and 18F-FDG Pet for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. Korean J Radiol 7 4 (2006) 249-256
21. Yun M., Choi H.S., Yoo E., Bong J.K., Ryu Y.H., and Lee J.D. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET. J Nucl Med 46 6 (2005) 953-957
22. De P.T., Flamen P., Van C.E., et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 29 4 (2002) 525-529
23. Jadvar H., Tatlidil R., Garcia A.A., and Conti P.S. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 58 3 (2003) 215-221
24. Kawamura T., Kusakabe T., Sugino T., et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92 3 (2001) 634-641
25. Boellaard R., Krak N.C., Hoekstra O.S., and Lammertsma A.A. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 45 9 (2004) 1519-1527
26. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45 9 (2004) 1431-1434
27. Koga H., Sasaki M., Kuwabara Y., et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 17 8 (2003) 733-738
28. Yamada A., Oguchi K., Fukushima M., Imai Y., and Kadoya M. Evaluation of 2-deoxy-2-[18F] fluoro-d-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 20 9 (2006) 597-604
29. Hur J., Park M.S., Lee J.H., et al. Diagnostic accuracy of multidetector row computed tomography in t- and n staging of gastric cancer with histopathologic correlation. J Comput Assist Tomogr 30 3 (2006) 372-377
30. Kim H.J., Kim A.Y., Oh S.T., et al. Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. Radiology 236 3 (2005) 879-885
31. The Japanese Gastric Cancer Association (JGCA). Introduction to JGCA gastric cancer treatment guidelines. Ref type: Report 2001.
32. Kim W.S., Kim Y.Y., Jang S.J., Kimm K., and Jung M.H. Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. J Korean Med Sci 15 4 (2000) 420-424
33. Lehnert T., Rudek B., Kienle P., Buhl K., and Herfarth C. Impact of diagnostic laparoscopy on the management of gastric cancer: prospective study of 120 consecutive patients with primary gastric adenocarcinoma. Br J Surg 89 4 (2002) 471-475
34. Hartgrink H.H., van d V., Putter H., et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 30 6 (2004) 643-649
35. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 1 (2006) 11-20
36. Schuhmacher C.P., Fink U., Becker K., et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91 5 (2001) 918-927
37. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
38. Shiraishi N., Inomata M., Osawa N., Yasuda K., Adachi Y., and Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 89 2 (2000) 255-261
39. Dwamena B.A., Sonnad S.S., Angobaldo J.O., and Wahl R.L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 213 2 (1999) 530-536
40. Halpern B.S., Schiepers C., Weber W.A., et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128 4 (2005) 2289-2297
41. Cerfolio R.J., Ojha B., Bryant A.S., Raghuveer V., Mountz J.M., and Bartolucci A.A. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non small cell lung cancer. Ann Thorac Surg 78 3 (2004) 1017-1023
42. Yuan S., Yu Y., Chao K.S., et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 47 8 (2006) 1255-1259
43. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 11 (1998) 1334-1336
44. Herrmann K., Ott K., Buck A.K., et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 48 12 (2007) 1945-1950